Long-Term Outcome in Adult Patients with Drug-Resistant Epilepsy Submitted to Vagus Nerve Stimulation

Samuele Santi,Filomena Fuggetta,Gabriella Colicchio,Manuela D'Ercole,Alessandro Izzo,Quintino Giorgio D'Alessandris,Benedetta Burattini,Renata Martinelli,Nicola Montano
DOI: https://doi.org/10.3390/brainsci14070639
IF: 3.333
2024-06-26
Brain Sciences
Abstract:Epilepsy treatment primarily involves antiseizure medications (ASMs) to eliminate seizures and improve the quality of life, but many patients develop drug-resistant epilepsy (DRE), necessitating alternative interventions. This study aimed to evaluate the long-term efficacy and safety of vagus nerve stimulation (VNS) in managing DRE. We retrospectively analyzed data from 105 adult patients treated at Agostino Gemelli Hospital from 1994 to 2022. Among the 73 patients with follow-up data, 80.8% were responders, experiencing significant reductions in seizure frequency over an average follow-up period of 9.4 years. Although 19.2% were non-responders, many of these patients still opted for generator replacements due to improvements in quality of life, such as fewer falls and shorter post-ictal periods. The overall complication rate was 12.3%, with most complications being mild and manageable. These findings suggest that VNS offers substantial long-term benefits for patients with DRE, improving seizure control and quality of life. This study underscores the importance of VNS as a viable long-term treatment option for DRE, highlighting its potential to significantly enhance patient outcomes and quality of life.
neurosciences
What problem does this paper attempt to address?
This paper primarily explores the long-term efficacy and safety of Vagus Nerve Stimulation (VNS) therapy for adult patients with Drug-Resistant Epilepsy (DRE). ### Research Objective The paper aims to evaluate the long-term effectiveness and safety of VNS in managing drug-resistant epilepsy. ### Key Findings - **Study Sample**: A retrospective analysis of data from 105 adult patients treated at Agostino Gemelli Hospital from 1994 to 2022. Among them, 73 patients had follow-up data. - **Response Rate**: Among these patients, 80.8% were identified as responders, experiencing a significant reduction in seizure frequency. The average follow-up period was 9.4 years. - **Non-Responders**: Although 19.2% of patients did not meet the criteria for responders, many non-responders still opted to replace the stimulator due to improvements in their quality of life, such as reduced fall frequency and shorter post-seizure recovery periods. - **Complications**: The overall complication rate was 12.3%, with most complications being mild and manageable. ### Conclusion The study results indicate that VNS provides substantial long-term benefits for patients with drug-resistant epilepsy, including improved seizure control and enhanced quality of life. This underscores the importance of VNS as a long-term treatment option for drug-resistant epilepsy and highlights its potential to significantly improve patient prognosis and quality of life. ### Methodological Features - **Study Design**: Retrospective study. - **Evaluation Metrics**: Primarily focused on the proportion of responders (patients with more than 50% reduction in seizure frequency). To comprehensively assess the impact of VNS therapy, the frequency and reasons for battery device replacement were also recorded. - **Complication Assessment**: The number and types of complications were documented. ### Discussion Points - **Long-Term Efficacy**: The study emphasizes the importance of long-term follow-up in evaluating treatment efficacy, particularly in observing sustained seizure reduction. - **Quality of Life Improvement**: Even though some patients did not meet the traditional "responder" criteria, they continued using VNS because the therapy improved their quality of life. - **Cognitive Function Improvement**: VNS therapy not only helps reduce seizures but may also improve cognitive function and emotional state. - **Reduction in Medication Burden**: By reducing the use of antiepileptic drugs, VNS can help alleviate medication side effects, thereby improving the overall quality of life for patients. - **Complication Management**: While some complications exist, most are mild and can be resolved with simple medical interventions. ### Limitations - **Retrospective Study Design**: The retrospective nature of the study limits the formal analysis of potential prognostic factors. - **Patient Attrition**: A significant number of patients were lost to follow-up. - **Quality of Life Assessment**: Systematic quality of life assessments were not conducted.